ES2177543T3 - Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. - Google Patents

Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos.

Info

Publication number
ES2177543T3
ES2177543T3 ES93907541T ES93907541T ES2177543T3 ES 2177543 T3 ES2177543 T3 ES 2177543T3 ES 93907541 T ES93907541 T ES 93907541T ES 93907541 T ES93907541 T ES 93907541T ES 2177543 T3 ES2177543 T3 ES 2177543T3
Authority
ES
Spain
Prior art keywords
mammals
eye
alpha
administration
alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907541T
Other languages
English (en)
Inventor
Mussie Elizabeth Wolde
Guadalupe Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2177543T3 publication Critical patent/ES2177543T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS PARA TRATAR GLAUCOMA Y/O HIPERTENSION OCULAR EN EL OJO DE LOS MAMIFEROS POR ADMINISTRACION AL OJO DE LOS MAMIFEROS DE LA COMPOSICION FARMACEUTICA DE LA INVENCION QUE CONTIENE COMO INGREDIENTE ACTIVO UNO O MAS COMPUESTOS ANTAGONISTAS MUSCARINICOS. EJEMPLOS DE ANTAGONISTAS MUSCARINICOS UTILIZADOS EN LA COMPOSICION FARMACEUTICA Y METODO DE TRATAMIENTO SON : 10H TIENO(3,4-B) (1,5)BENZODIAZEPIN NA 4,9 ETIL) (TELENZEPINA); 5,11 DIHIDRO AZINIL) NA (PIRENZEPINA); 11 IDINIL] BENZODIZEPIN IETILAMINO) METIL] 50) DEXTROROTATORIA; UNA SAL OPTALMICAMENTE ACEPTABLE DE 4 IFENILACETOXI OHEXIL, -(ALFA)-FENIL ); CICLOHEXANOMETANOL, (ALFA)-FENIL, (ALFA)-[3-(1 L) PIN NIL] [1,4]BENZODIAZEPINA ILAMINO)METIL] MONOMETANOSULFONATO (AF-DX 384); 1,8 BIS [6 RURO (METOCTRAMINA) Y NAFTO[2,3 C] FURAN 3S -[3 (ALFA), 3A (ALFA), 4 (BETA)[1E, 2(2R*, 6S*)],4A (BETA), 8A (ALFA), 9A (ALFA)]] (HIMBACINA).
ES93907541T 1992-03-18 1993-03-16 Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. Expired - Lifetime ES2177543T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/853,374 US5716952A (en) 1992-03-18 1992-03-18 Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists

Publications (1)

Publication Number Publication Date
ES2177543T3 true ES2177543T3 (es) 2002-12-16

Family

ID=25315868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907541T Expired - Lifetime ES2177543T3 (es) 1992-03-18 1993-03-16 Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos.

Country Status (8)

Country Link
US (1) US5716952A (es)
EP (1) EP0634932B1 (es)
JP (1) JPH07504915A (es)
AT (1) ATE219367T1 (es)
AU (1) AU666536B2 (es)
DE (1) DE69332048T2 (es)
ES (1) ES2177543T3 (es)
WO (1) WO1993018772A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229961A (ja) 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
CA2463628A1 (en) * 2001-10-18 2003-04-24 Schering Corporation Himbacine analogues as thrombin receptor antagonists
EP1781300A1 (en) 2004-07-16 2007-05-09 ProteoSys AG Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
EP2387405A2 (en) 2009-01-13 2011-11-23 ProteoSys AG Pirenzepine as an agent in cancer treatment
SG192648A1 (en) * 2011-02-09 2013-09-30 Singapore Health Serv Pte Ltd Transglutaminase-2 inhibitors and uses thereof
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
EP3970694A1 (en) 2017-05-11 2022-03-23 Vyluma Inc. Atropine pharmaceutical compositions
EP3713530A4 (en) * 2017-11-21 2021-08-18 Sydnexis, Inc. OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT
CA3189821A1 (en) 2020-08-04 2022-02-10 Santen Pharmaceutical Co., Ltd. Agent for treating myopia, preventing myopia and/or suppressing myopia progression
KR20230087514A (ko) 2020-10-14 2023-06-16 산텐 세이야꾸 가부시키가이샤 안정한 의약 조성물
JPWO2023190653A1 (es) 2022-03-30 2023-10-05
US20250214992A1 (en) 2022-03-30 2025-07-03 Santen Pharmaceutical Co., Ltd. High-purity compound production method and purification method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918407A (en) * 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodics specific for upper gastrointestinal pain and spasm
US3467756A (en) * 1967-03-16 1969-09-16 Merck & Co Inc Composition and method for treating glaucoma
DE1795183B1 (de) * 1968-08-20 1972-07-20 Thomae Gmbh Dr K 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4565821A (en) * 1983-03-21 1986-01-21 The Texas A&M University System Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones
IT1212742B (it) * 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
DE3409237A1 (de) * 1984-03-14 1985-09-19 Dr. Karl Thomae Gmbh, 7950 Biberach Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4886815A (en) * 1984-06-20 1989-12-12 Schachar Ronald A Treatment and prevention of retinal edema with dopaminergic antagonists
DE3626095A1 (de) * 1986-07-31 1988-02-11 Thomae Gmbh Dr K Neue substituierte pyrido(2,3-b)(1,4)benzodiazepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE183085T1 (de) * 1989-06-21 1999-08-15 Univ Pennsylvania Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5153205A (en) * 1990-10-01 1992-10-06 Merck & Co., Inc. Method to reduce introacular pressure without causing miosis

Also Published As

Publication number Publication date
ATE219367T1 (de) 2002-07-15
AU3810993A (en) 1993-10-21
AU666536B2 (en) 1996-02-15
WO1993018772A1 (en) 1993-09-30
DE69332048D1 (de) 2002-07-25
JPH07504915A (ja) 1995-06-01
EP0634932B1 (en) 2002-06-19
DE69332048T2 (de) 2003-01-23
US5716952A (en) 1998-02-10
EP0634932A1 (en) 1995-01-25

Similar Documents

Publication Publication Date Title
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR035863A1 (es) Ligandos receptores de melanocortina
SV2003000697A (es) Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb
ES2182973T3 (es) Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.
PA8591701A1 (es) Derivados de pirrolopirimidina
AR012964A1 (es) Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales
DE69833451D1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
SE9904508D0 (sv) New compounds
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
AR018033A1 (es) Analogos 13-oxa prostaglandinas, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
BR0314635A (pt) Derivados de piridina como moduladores de receptores de cb2
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
MXPA04000839A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1110554A4 (en) MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma